3- tert- butoxycarbonylmethyl- 5- (4- (2- (N- methyl- N- (2- pyridyl)amino)ethoxy)benzyl)thiazolidine- 2,4- dione

a peroxisome proliferator-activated receptor gamma partial agonist; structure in first source

Also Known As:

CMHX008

Networked: 3 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Aminopyridines: 77
    - 3-tert-butoxycarbonylmethyl-5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione: 3
- Sulfur Compounds: 278
  - Thiazoles: 392
    - Thiazolidinediones: 2250
      - 3-tert-butoxycarbonylmethyl-5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - Thiazolidinediones: 2250
        3-tert-butoxycarbonylmethyl-5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione: 3
  - Pyridines: 88
    - Aminopyridines: 77
      - 3-tert-butoxycarbonylmethyl-5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione: 3

Experts

1.	Li, Jibin: 3 articles (01/2021 - 01/2014)
2.	Wu, Chaodong: 3 articles (01/2021 - 01/2014)
3.	Xiao, Xiaoqiu: 3 articles (01/2021 - 01/2014)
4.	Cao, Xuemei: 2 articles (01/2021 - 09/2018)
5.	Hou, Yi: 2 articles (01/2021 - 09/2018)
6.	Hu, Xiangnan: 2 articles (09/2018 - 01/2014)
7.	Diao, Junlin: 1 article (01/2021)
8.	Gan, Yongjun: 1 article (01/2021)
9.	Mao, Min: 1 article (01/2021)
10.	Su, Hong: 1 article (01/2021)

Related Diseases

1.	Insulin Resistance 09/01/2018 - "CMHX008, a PPARγ partial agonist, enhances insulin sensitivity with minor influences on bone loss." 01/01/2014 - "CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo." 09/01/2018 - "Mice treated with CMHX008 showed insulin sensitization similar to that of mice treated with rosiglitazone, which was related to the significant inhibition of PPARγ Ser273 phosphorylation and improved insulin sensitivity by facilitating the phosphorylation of insulin receptor and Akt in adipose tissues. "
2.	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 01/01/2021 - "HFD-fed mice treated with rosiglitazone or CMHX008 had significantly improved cardiac function, but rosiglitazone induced higher expression of ANP and βMHC and hypertrophic cardiomyopathy, while CMHX008 did not. "
3.	Glucose Intolerance 01/01/2014 - "Treatment of CMHX008 and rosiglitazone protected mice from high fat diet (HFD)-induced glucose intolerance, hyperinsulinemia and inflammation. "
4.	Inflammation (Inflammations) 01/01/2014 - "Treatment of CMHX008 and rosiglitazone protected mice from high fat diet (HFD)-induced glucose intolerance, hyperinsulinemia and inflammation. "
5.	Hypertrophy 01/01/2021 - "The full agonist rosiglitazone prevents cardiac dysfunction at the expense of compensatory hypertrophy, while the partial agonist CMHX008 shared a comparable protective effect without altering the structure of cardiomyocytes."

Related Drugs and Biologics

1.	Rosiglitazone (Avandia)
2.	Insulin Receptor
3.	Atrial Natriuretic Factor (ANF)
4.	Insulin (Novolin)
5.	Peroxisome Proliferator-Activated Receptors (PPAR)